We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cholesterol-Lowering Drug an Unexpected Antibiotic

By Biotechdaily staff writers
Posted on 26 Feb 2008
Microbiologists have found that treating Staphylococcus aureus with a cholesterol-lowering drug inhibited the synthesis of the golden-colored pigment staphyloxanthin, and rendered the bacteria more susceptible to destruction by the immune system.

An international team of investigators based their attack on S. More...
aureus on earlier findings that a strain of the bacteria lacking the golden pigment was easier to kill. Since the pathway for production of staphyloxanthin in the bacteria is similar to that for synthesis of cholesterol in humans, the investigators examined the effect of drugs that inhibit cholesterol synthesis.

They reported in the February 14, 2008, online edition of the journal Science that of eight different drug compounds tested, three blocked pigment production in S. aureus. Treatment of mice infected with S. aureus with one of the compounds reduced bacterial population by 98%.

Since stopping pigment production caused the reduction in virulence, this treatment may not cause selective pressures on the population, which often leads to antibiotic resistance. Furthermore, this method targets only S. aureus, reducing possible side effects.

"I looked at the metabolic pathway and noticed that it was similar to the one for the production of cholesterol in humans,” said Dr. Eric Oldfield, professor of chemistry at the University of Illinois (Urbana-Champaign, USA). "This is an entirely new approach that seems to work in animals, and now we need to take the next step to explore if it will work in humans.”


Related Links:
University of Illinois

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.